Healthcare Services

Thyroid Eye Disease Market Growth Influenced by Thyroid Disorder Trends

April 28, 2026April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Thyroid Eye Disease (TED) Market Between 2026 And 2030?

The market for thyroid eye disease (ted) has experienced robust expansion over the past few years. Projections indicate its value will escalate from $2.29 billion in 2025 to $2.44 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.6%. This historical growth is largely due to the rising incidence of autoimmune thyroid conditions, enhanced identification of ted symptoms in clinical settings, broader application of corticosteroid treatments, the expansion of ophthalmology services, and an increase in patient referrals from endocrinology clinics.

The thyroid eye disease (ted) market size is poised for significant expansion in the upcoming years. It is projected to reach $3.12 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.3%. This anticipated growth during the forecast period stems from factors such as the increasing uptake of novel biologics like teprotumumab, rising investments in autoimmune disease research, the broader availability of minimally invasive surgical solutions, a growing emphasis on quality-of-life outcomes, and increasing demand for personalized ted therapies. Noteworthy trends in the forecast period include the increasing adoption of targeted biologic therapies, a rise in the use of combination treatment approaches, a growing focus on early disease intervention, the expansion of specialized ophthalmic care, and enhanced patient-centered treatment models.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21300&type=smp

Which Strong Drivers Are Impacting The Thyroid Eye Disease (TED) Market Growth?

The anticipated increase in thyroid disorders is projected to fuel the expansion of the thyroid eye disease (TED) market moving ahead. These disorders encompass health issues impacting the thyroid gland’s operation, causing hormonal imbalances and manifesting as conditions like hypothyroidism, hyperthyroidism, goiter, and thyroid eye disease. The surge in thyroid disorders is attributable to several elements, including elevated iodine consumption, autoimmune diseases, inherited genetic tendencies, and enhanced public awareness resulting in more accurate diagnoses. Thyroid Eye Disease (TED) itself adds to the growing number of thyroid disorder instances, being a frequent and severe complication of Graves’ disease, thus amplifying the total impact and recognition of conditions linked to the thyroid. As an illustration, in May 2024, the Canadian Cancer Society, a Canada-based non-profit, community-based organization, reported that for 2024, approximately 6,600 new cases of thyroid cancer are anticipated to be diagnosed in Canada, alongside an estimated 280 projected fatalities. Consequently, the increase in thyroid disorders is indeed stimulating the expansion of the thyroid eye disease (TED) market.

How Are Segments Identified Within The Thyroid Eye Disease (TED) Market Segment Framework?

The thyroid eye disease (ted) market covered in this report is segmented –

1) By Treatment Type: Medical, Surgical, Combination Of Medical And Surgical

2) By Disease Severity: Mild, Moderate, Severe

3) By Drug Type: Biologics, Small Molecules, Other Drug Types

4) By Route Of Administration: Oral, Intravenous, Subcutaneous

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Medical: Corticosteroids, Teprotumumab, Antithyroid Medications

2) By Surgical: Orbital Decompression Surgery, Eyelid Surgery, Strabismus Surgery

3) By Combination Of Medical and Surgical: Combination of Corticosteroids and Orbital Decompression, Combination of Teprotumumab and Eyelid Surgery

Which Trends Are Contributing To Changes In The Thyroid Eye Disease (TED) Market?

Major companies within the thyroid eye disease (TED) market are concentrating on advanced products, such as monoclonal antibody therapies, to devise more effective, targeted treatments capable of reducing inflammation, improving proptosis, and enhancing overall patient outcomes. Monoclonal antibody therapies are treatments utilizing laboratory-engineered antibodies designed to replicate the immune system’s capability to target and neutralize specific pathogens or abnormal cells. For instance, in September 2024, Amgen Inc., a US-based biotechnology company, disclosed that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for TEPEZZA (teprotumumab) for managing active thyroid eye disease (TED), a rare and potentially vision-threatening autoimmune disorder. It represents the first and only FDA-approved therapy specifically for TED, providing a targeted treatment that aids in decreasing inflammation, swelling, and other debilitating symptoms linked to the condition. This approval holds particular significance for patients in Japan, as it offers a new, effective choice to manage TED, a rare and progressive condition responsible for severe eye bulging, vision difficulties, and eye pain.

Who Are The Companies Competing Within The Thyroid Eye Disease (TED) Market?

Major companies operating in the thyroid eye disease (ted) market are Viridian Therapeutics Inc, Tourmaline Bio Inc, Sling Therapeutics Inc, Immunovant Inc, Hoffmann-La Roche AG, H Lundbeck A S, Alumis Inc, Changchun GeneScience Pharmaceutical Co Ltd, Minghui Pharmaceutical Inc, Amgen Inc, Crinetics Pharmaceuticals Inc, Ollin Biosciences Inc, Lycia Therapeutics Inc, Inflammasome Therapeutics Inc, Novartis Pharmaceuticals Corp, AdvanceCOR Inc, Worg Pharmaceuticals Inc, AV7 Limited, EVOQ Therapeutics Inc, ValenzaBio Inc, Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Sanofi SA, Alexion Pharmaceuticals Inc, Septerna Corporation

Get The Full Thyroid Eye Disease (TED) Market Report:

https://www.thebusinessresearchcompany.com/report/thyroid-eye-disease-ted-global-market-report

Which Region Dominates The Thyroid Eye Disease (TED) Market By Market Share?

North America was the largest region in the thyroid eye disease (TED) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid eye disease (ted) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Thyroid Eye Disease (TED) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/thyroid-eye-disease-ted-global-market-report

Browse Through More Reports Similar to the Global Thyroid Eye Disease (TED) Market 2026, By The Business Research Company

Eye Melanoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/eye-melanoma-global-market-report

Thyroid Function Test Market Report

https://www.thebusinessresearchcompany.com/report/thyroid-function-test-global-market-report

Thyroid Cancer Diagnostics Market Report

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795